DK1261320T3 - Micellare farmaceutiske sammesætninger til bukkal og pulmonal anvendelse - Google Patents

Micellare farmaceutiske sammesætninger til bukkal og pulmonal anvendelse

Info

Publication number
DK1261320T3
DK1261320T3 DK01919686T DK01919686T DK1261320T3 DK 1261320 T3 DK1261320 T3 DK 1261320T3 DK 01919686 T DK01919686 T DK 01919686T DK 01919686 T DK01919686 T DK 01919686T DK 1261320 T3 DK1261320 T3 DK 1261320T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
buccal
disclosed
micellar pharmaceutical
pulmonary use
Prior art date
Application number
DK01919686T
Other languages
Danish (da)
English (en)
Inventor
Pankaj Modi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Application granted granted Critical
Publication of DK1261320T3 publication Critical patent/DK1261320T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01919686T 2000-03-06 2001-02-21 Micellare farmaceutiske sammesætninger til bukkal og pulmonal anvendelse DK1261320T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/519,285 US6375975B1 (en) 1998-12-21 2000-03-06 Pharmaceutical compositions for buccal and pulmonary application
PCT/IB2001/000515 WO2001066085A2 (en) 2000-03-06 2001-02-21 Micellar pharmaceutical compositions for buccal and pulmonary application

Publications (1)

Publication Number Publication Date
DK1261320T3 true DK1261320T3 (da) 2008-10-20

Family

ID=24067646

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01919686T DK1261320T3 (da) 2000-03-06 2001-02-21 Micellare farmaceutiske sammesætninger til bukkal og pulmonal anvendelse

Country Status (12)

Country Link
US (1) US6375975B1 (https=)
EP (1) EP1261320B1 (https=)
JP (1) JP2003525891A (https=)
AT (1) ATE398998T1 (https=)
AU (1) AU783431B2 (https=)
CA (1) CA2401942C (https=)
DE (1) DE60134535D1 (https=)
DK (1) DK1261320T3 (https=)
ES (1) ES2309059T3 (https=)
MX (1) MXPA02008749A (https=)
PT (1) PT1261320E (https=)
WO (1) WO2001066085A2 (https=)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2003097094A1 (en) * 2002-05-21 2003-11-27 Anadis Ltd Method of prophylaxis of infection
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
EP1369113B1 (en) * 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Solubilisation of drugs in HFA propellant by means of emulsions
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
ES2660172T3 (es) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
CN101309668A (zh) * 2005-11-30 2008-11-19 健乐克斯医药公司 经口吸收的药物制剂和用药方法
TWI299993B (en) * 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
EP2015632B1 (en) * 2006-04-19 2015-12-02 Mist Pharmaceuticals, LLC Stable hydroalcoholic oral spray formulations and methods
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
JP2010513525A (ja) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド 安定な抗嘔吐経口噴霧製剤および方法
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2152241A4 (en) * 2007-04-30 2012-11-14 Agency Science Tech & Res PROCESS FOR DELIVERING A PROTEIN INTO A CELL
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CN101801346A (zh) * 2007-05-10 2010-08-11 诺瓦德尔药品公司 抗失眠症组合物及方法
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
EP2211842B1 (en) * 2007-10-24 2015-08-12 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
CA2770298C (en) 2008-08-13 2017-06-20 Metabasis Therapeutics, Inc. Glucagon antagonists
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
HUP0900482A2 (en) 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
IN2012DN05145A (https=) 2009-11-19 2015-10-23 Solis Biodyne
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
JP6692293B2 (ja) 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおける酵素活性を増大するための方法および組成物
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
JPWO2016153015A1 (ja) * 2015-03-25 2018-05-10 株式会社ファルマクリエ神戸 高分子薬効成分を含有した口腔内施用物および口腔内への高分子薬効成分の投与方法
CA3026108A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53107408A (en) 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
JPH0753661B2 (ja) * 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
DK179286D0 (da) 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
CA2033725C (en) 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
IT1255449B (it) 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
PL323931A1 (en) * 1995-06-07 1998-04-27 Alliance Pharma Compositions of reversed emulsion of fluorine derivatives of hydrocarbons for use as drug delivering carriers
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6290987B1 (en) * 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
NZ514319A (en) * 1999-03-19 2002-11-26 Generex Pharm Inc Proteinic pharmaceutical agent solubilized in aerosol propellant in a pressurized container

Also Published As

Publication number Publication date
US6375975B1 (en) 2002-04-23
JP2003525891A (ja) 2003-09-02
MXPA02008749A (es) 2003-04-14
PT1261320E (pt) 2008-09-03
EP1261320A2 (en) 2002-12-04
ATE398998T1 (de) 2008-07-15
AU783431B2 (en) 2005-10-27
CA2401942A1 (en) 2001-09-13
ES2309059T3 (es) 2008-12-16
WO2001066085A3 (en) 2002-04-11
CA2401942C (en) 2010-06-29
EP1261320B1 (en) 2008-06-25
AU4674601A (en) 2001-09-17
DE60134535D1 (de) 2008-08-07
WO2001066085A2 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
DK1261320T3 (da) Micellare farmaceutiske sammesætninger til bukkal og pulmonal anvendelse
MXPA02011436A (es) Composiciones farmaceuticas micelares para aplicacion bucal y pulmonar.
ATE243498T1 (de) Aerosol formulierungen für buccale und pulmonale anwendung
WO2004016244A3 (en) Pharmaceutical compositions for buccal delivery of pain relief medications
IL150986A0 (en) 1,2,3,4,- tetrahydroisoquinoline derivatives
NO20053143L (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
MXPA03004780A (es) Nuevas sulfamidas.
MXPA04000226A (es) Composiciones generadoras de mousse que contienen agentes de amonio cuaternario.
CA2414018A1 (en) 2-aminocarbonyl-9h-purine derivatives
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
DK1611892T3 (da) Farmaceutiske sammensætninger indeholdende drospirenon
DK1157037T3 (da) GCSF-konjugater
PL367094A1 (en) Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
MXPA04001968A (es) Agentes antidiabeticos.
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
WO2004016243A3 (en) Methods of administering and enhancing absorption of pharmaceutical agents
CA2419314A1 (en) Preparation of risperidone
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
BG106239A (en) Improved pharmaceutical formulations
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
WO2002094856A3 (en) Gpe analogs and peptidomimetics
CN109199898A (zh) 含氧化剂的组合物及其使用方法
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı